Cancer Summaries and Commentaries™: Report from Toronto and Chicago on Advances in Gynecologic Oncology

Release Date: November 30, 2020
Expiration Date: November 30, 2021
Media: Internet - based

Activity Overview

This online activity is designed to update clinicians on data presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO 2020), held March 28 to March 31, 2020, in Toronto, Canada, and the American Society of Clinical Oncology Virtual Scientific Program (ASCO 2020), held May 29 to June 2, 2020. The activity will help facilitate critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 4 abstracts from these meetings that focus on ovarian and endometrial cancer. For each abstract, a text summary of key clinical data is accompanied by perspectives from expert thought leaders who provide insights into how clinicians can apply these findings to their clinical practice to improve patient care.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with gynecologic malignancies. Gynecologic oncologists, surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment and management of patients with gynecologic malignancies will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe recent data from clinical trials investigating novel therapies for the treatment of gynecologic cancers
• Discuss the real-world implications of recently reported data from clinical trials in the management of patients with gynecologic cancers
• Explain the study design and eligibility criteria of ongoing clinical trials investigating therapies for the treatment of patients with gynecologic cancers
• Implement strategies for monitoring, identifying, and mitigating the risk of treatment-related toxicities associated with therapies used in the treatment of gynecologic cancers

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Bradley J. Monk, MD, FACS, FACOG
Professor and Director, Division of Gynecologic Oncology
Creighton University School of Medicine at St. Joseph's Hospital and Medical Center
Professor on the Clinical Scholar Track
University of Arizona College of Medicine
Physician, Arizona Oncology (US Oncology Network)
Medical Director of Gynecologic Oncology Research, US Oncology
Co-director, GOG-Partners
Member, Board of Directors, GOG-Foundation
Phoenix, AZ

Disclosures: Consultant: AbbVie, Agenus, Akesobio, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana Therapeutics, Myriad Genetics, Pfizer, Puma Biotechnology, Roche/Genentech, Starton Therapeutics, Tesaro/GlaxoSmithKline, Vavotar Life Sciences, VBL Therapeutics; Speakers Bureau: AstraZeneca, Clovis Oncology, Eisai, Merck, Roche/Genentech, Tesaro/GlaxoSmithKline

Susana M. Campos, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant Research Support: AstraZeneca, Eisai, GlaxoSmithKline

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.